Oct 20, 2026 06:49AM
Oct 19, 2026 08:00AM
Oct 19, 2026 08:00AM
Sep 4, 2026 08:00AM
Aug 20, 2026 07:06AM
Aug 20, 2026 07:05AM
Aug 20, 2026 07:00AM UroGen strikes option deal with IntraGel, invests up to $7M
Aug 20, 2026 07:00AM
Aug 20, 2026 06:57AM
Aug 17, 2026 08:04AM
Aug 17, 2026 08:00AM
Aug 5, 2026 08:00AM
Jul 15, 2026 08:00AM
Jul 15, 2026 08:00AM UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103
Jul 9, 2026 06:49AM
Jul 8, 2026 08:02AM
Jul 8, 2026 08:00AM
Jun 5, 2026 08:00AM
Jun 3, 2026 06:53AM
Jun 2, 2026 08:00AM
Jun 2, 2026 08:00AM UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution
May 15, 2026 08:00AM
May 15, 2026 08:00AM
May 13, 2026 08:02AM
May 13, 2026 08:00AM
May 11, 2026 07:12AM
May 6, 2026 08:00AM
Mar 30, 2026 08:05AM UroGen publishes 24-month ZUSDURI trial data in Journal of Urology
Mar 30, 2026 08:00AM
Mar 6, 2026 04:10PM
Mar 2, 2026 08:04AM
Mar 2, 2026 08:00AM
Feb 27, 2026 08:30AM
Feb 24, 2026 04:05PM
Feb 23, 2026 08:00AM UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026
Feb 4, 2026 08:00AM
Jan 5, 2026 08:00AM
Dec 22, 2025 07:06AM
Dec 5, 2025 08:00AM
Nov 6, 2025 08:00AM
Nov 6, 2025 07:58AM
Nov 6, 2025 07:58AM UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial
Nov 4, 2025 08:00AM
Oct 30, 2025 08:00AM
Oct 27, 2025 08:00AM
Oct 24, 2025 08:29AM
Oct 2, 2025 08:02AM
Oct 2, 2025 08:00AM
Sep 8, 2025 08:00AM UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aug 21, 2025 08:00AM

335,369 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All